These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 7022829)

  • 21. Effect of anti-T-cell globulin on GVHD in leukemic patients treated with BMT.
    Rodt H; Kolb HJ; Netzel B; Haas RJ; Wilms K; Götze CB; Link H; Thierfelder S
    Transplant Proc; 1981 Mar; 13(1 Pt 1):257-61. PubMed ID: 7022835
    [No Abstract]   [Full Text] [Related]  

  • 22. Graft-vs-host reaction in a xenogeneic combination: mechanism of the reaction.
    Constantine RI; Nakouz J; Maclean LD; Gordon J
    J Immunol; 1971 Jun; 106(6):1660-4. PubMed ID: 4397382
    [No Abstract]   [Full Text] [Related]  

  • 23. [New studies concerning physiopathology and prevention of graft versus host reaction].
    Mathe G; Gutierrez-Romero M; Kiger N; Garcia-Giralt E; Florentin I; Halle-Pannenko O
    Ann Inst Pasteur (Paris); 1972 Jul; 123(1):123-4. PubMed ID: 4404826
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical uses of anti-thymocyte globulin (ATGAM), Part II.
    Gilbert C
    N C Med J; 1984 Dec; 45(12):773-5. PubMed ID: 6392895
    [No Abstract]   [Full Text] [Related]  

  • 25. Prevention and therapy of graft-versus-host disease.
    N Engl J Med; 1982 Aug; 307(6):376-7. PubMed ID: 7045672
    [No Abstract]   [Full Text] [Related]  

  • 26. Immunology of experimental transplantation in prite animals.
    Balner H
    Ann N Y Acad Sci; 1969 Jul; 162(1):437-52. PubMed ID: 4979564
    [No Abstract]   [Full Text] [Related]  

  • 27. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
    Pelot MR; Pearson DA; Swenson K; Zhao G; Sachs J; Yang YG; Sykes M
    Biol Blood Marrow Transplant; 1999; 5(3):133-43. PubMed ID: 10392959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous IgG to prevent graft-versus-host disease after bone marrow transplantation.
    N Engl J Med; 1991 Feb; 324(9):631-3. PubMed ID: 1992325
    [No Abstract]   [Full Text] [Related]  

  • 29. Suppression of graft-versus-host disease by naturally occurring regulatory T cells.
    Zeng D; Lan F; Hoffmann P; Strober S
    Transplantation; 2004 Jan; 77(1 Suppl):S9-S11. PubMed ID: 14726761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytotoxicity against human leukaemic cells. I. Demonstration of antibody-dependent lymphocyte killing of human allogeneic myeloblasts.
    Hersey P; MacLennan IC; Campbell AC; Harris R; Freeman CB
    Clin Exp Immunol; 1973 Jun; 14(2):159-67. PubMed ID: 4577850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Bone marrow transplantation for severe aplastic anemia].
    Bullorsky EO; Bonduel M; Shanley C; Figueroa C; Stemmelin G; Del Pozo A; Ceresetto J; Delfino S; Puppo M; Muriel FS
    Medicina (B Aires); 1998; 58(2):130-4. PubMed ID: 9706244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Donor bone marrow infusion suppresses alloantibody response in RATG-treated recipients: a correlate of long survival.
    Thomas JM; Carver FM; Cunningham PR; Gross U; Verbanac KM; Rebellato LM; Riley R; Thomas FT
    Transplant Proc; 1993 Feb; 25(1 Pt 1):342-3. PubMed ID: 8438326
    [No Abstract]   [Full Text] [Related]  

  • 33. 'Purging' of bone marrow and immunosuppression.
    Janossy G
    Br Med Bull; 1984 Jul; 40(3):247-53. PubMed ID: 6380636
    [No Abstract]   [Full Text] [Related]  

  • 34. The effect of pretreatment of allogeneic bone marrow graft recipients with antilymphocytic serum on the acute graft-versus-host reaction in monkeys.
    van Bekkum DW; Balner H; Dicke KA; van den Berg FG; Prinsen GH; Hollander CF
    Transplantation; 1972 Apr; 13(4):400-7. PubMed ID: 4552363
    [No Abstract]   [Full Text] [Related]  

  • 35. Impact of AB0-blood group incompatibility on the outcome of recipients of bone marrow transplants from unrelated donors in the Japan Marrow Donor Program.
    Kimura F; Sato K; Kobayashi S; Ikeda T; Sao H; Okamoto S; Miyamura K; Mori S; Akiyama H; Hirokawa M; Ohto H; Ashida H; Motoyoshi K;
    Haematologica; 2008 Nov; 93(11):1686-93. PubMed ID: 18835834
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclosporin A: use in preventing graft versus host disease.
    Klemm P
    Oncol Nurs Forum; 1985; 12(5):25-32. PubMed ID: 3898028
    [No Abstract]   [Full Text] [Related]  

  • 37. Proposal for a world bank of reactive cells from bone marrow.
    Dausset J
    Transplant Proc; 1974 Dec; 6(4):429-30. PubMed ID: 4155157
    [No Abstract]   [Full Text] [Related]  

  • 38. Differential sensitivity of T lymphocytes and hematopoietic precursor cells to photochemotherapy with 8-methoxypsoralen and ultraviolet A light.
    Mabed M; Coffe C; Racadot E; Angonin R; Pavey JJ; Tiberghien P; Herve P
    Ann Hematol; 2006 Jan; 85(1):17-24. PubMed ID: 16208471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prognosis and course of bone marrow transplantation].
    Ostendorf P
    Verh Dtsch Ges Inn Med; 1986; 92():431-4. PubMed ID: 3544568
    [No Abstract]   [Full Text] [Related]  

  • 40. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
    Johnson BD; Drobyski WR; Truitt RL
    Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.